Clearmind Medicine Inc.
CMNDHealthcare|Biotechnology|CA
$5.58
-0.27 (-4.55%)
DCF Value
$8.03
Tangible Book / Share
$65.03
Cash / Share
$80.54
Financials
Financial Snapshot
Market Cap
$2.8M
Enterprise Value
-$7.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$7.5M
Cash & Investments
$15.9M
Net Cash
$14.1M
Free Cash Flow (TTM)
-$7.5M
Operating CF (TTM)
-$7.5M
Debt/Equity
0.14
Cash Runway & Burn Rate
Cash on Hand
$15.9M
Quarterly Burn
$1.9M
Monthly Burn
$628.1K
Est. Runway
~8.5 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $79.9K | $56.2K | $522.51 | $247.6K | $3.7M | $437.8K | $5.5M | $9.6M | $5.6M | $15.9M | |
| Operating Cash Flow | -$9.1K | -$80.5K | -$47.9K | -$198.5K | -$2.1M | -$5.1M | -$6.3M | -$6.8M | -$4.7M | -$7.5M | |
| Free Cash Flow | -$27.5K | -$180.5K | -$55.4K | -$206.0K | -$2.2M | -$5.1M | -$6.3M | -$6.8M | -$4.7M | -$7.5M | |
| Capital Expenditure | -$18.4K | -$100.0K | -$7.6K | -$7.5K | -$169.4K | -$7.5K | $0.00 | $0.00 | $0.00 | $4.00 | |
| Financing Cash Flow | $130.0K | $158.5K | $0.00 | $449.4K | $5.4M | $694.5K | $11.7M | $8.7M | $2.6M | $18.3M |
R&D Spending
R&D (TTM)
$2.3M
R&D Intensity
—
R&D Growth vs Prior
+11.7%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $635.4K | $4.4M | $1.5M | $1.4M | $2.0M | $2.3M | |
| SG&A | $6.5K | $259.2K | $104.1K | $230.1K | $3.0M | $4.5M | $4.7M | $4.3M | $3.6M | $6.5M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $2.5K | $119.6K | $57.4K | $51.1K | $49.4K | $54.3K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$2.5K | -$119.6K | -$57.4K | -$51.1K | -$49.4K | -$54.3K | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $635.4K | $4.4M | $1.5M | $1.4M | $2.0M | $2.3M | |
| SG&A | $6.5K | $259.2K | $104.1K | $230.1K | $3.0M | $4.5M | $4.7M | $4.3M | $3.6M | $6.5M | |
| Operating Income | -$6.5K | -$259.2K | -$104.1K | -$230.1K | -$3.6M | -$9.0M | -$6.3M | -$5.7M | -$5.7M | -$8.9M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.8K | $0.00 | $36.2K | $19.5K | $13.6K | |
| Pretax Income | -$6.5K | -$198.1K | -$104.1K | -$230.1K | -$3.7M | -$9.9M | -$8.6M | -$4.9M | -$3.8M | -$7.5M | |
| Net Income | -$6.5K | -$198.1K | -$104.1K | -$230.1K | -$3.7M | -$9.9M | -$8.6M | -$5.3M | -$3.9M | -$7.5M | |
| EPS (Diluted) | -17.20 | -588.00 | -270.08 | -406.08 | -3784.80 | -7331.52 | -1360.56 | -54.24 | -24.24 | -89.20 | |
| EBITDA | -$6.5K | -$198.1K | -$104.1K | -$230.1K | -$3.7M | -$9.8M | -$8.5M | -$4.8M | -$3.7M | -$8.2M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.16 | 0.20 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79.9K | $56.2K | $522.51 | $247.6K | $3.7M | $174.8K | $5.4M | $9.2M | $3.9M | $12.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $263.0K | $86.1K | $402.8K | $1.7M | $3.9M | |
| Total Current Assets | $86.3K | $62.6K | $2.9K | $249.9K | $4.0M | $590.0K | $5.8M | $9.9M | $5.9M | $16.6M | |
| Total Assets | $100.6K | $188.1K | $135.5K | $384.8K | $4.2M | $1.1M | $6.0M | $10.1M | $6.1M | $16.9M | |
| Total Current Liabilities | $51.3K | $5.8K | $33.8K | $10.0K | $288.2K | $2.6M | $5.0M | $5.8M | $4.9M | $3.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $51.3K | $5.8K | $33.8K | $10.0K | $288.2K | $2.6M | $5.0M | $5.8M | $4.9M | $4.0M | |
| Stockholders' Equity | $49.4K | $182.2K | $101.6K | $374.8K | $3.9M | -$1.5M | $983.5K | $4.3M | $1.2M | $13.0M | |
| Retained Earnings | -$5.2K | -$153.4K | -$232.8K | -$405.1K | -$3.6M | -$13.8M | -$18.8M | -$33.4M | -$27.9M | -$34.7M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.1K | -$80.5K | -$47.9K | -$198.5K | -$2.1M | -$5.1M | -$6.3M | -$6.8M | -$4.7M | -$7.5M | |
| Capital Expenditure | -$18.4K | -$100.0K | -$7.6K | -$7.5K | -$169.4K | -$7.5K | $0.00 | $0.00 | $0.00 | $4.00 | |
| Free Cash Flow | -$27.5K | -$180.5K | -$55.4K | -$206.0K | -$2.2M | -$5.1M | -$6.3M | -$6.8M | -$4.7M | -$7.5M | |
| Investing Cash Flow | -$18.4K | -$100.0K | -$7.6K | -$3.8K | -$184.0K | -$7.5K | -$26.2K | -$331.4K | -$542.0K | -$2.2M | |
| Financing Cash Flow | $130.0K | $158.5K | $0.00 | $449.4K | $5.4M | $694.5K | $11.7M | $8.7M | $2.6M | $18.3M | |
| Issuance of Stock | $127.2K | $160.1K | $0.00 | $449.4K | $5.4M | $790.7K | $11.1M | $3.1M | $415.0K | $7.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$96.2K | -$40.9K | -$59.3K | $2.2M | $10.9M | |
| Stock Based Comp. | $0.00 | $112.3K | $0.00 | $0.00 | $619.9K | $1.6M | $508.1K | $1.4M | $805.8K | $1.6M | |
| Net Change in Cash | $102.5K | -$21.9K | -$55.4K | $247.1K | $3.1M | -$4.4M | $5.3M | $1.6M | -$2.7M | $8.7M |
Dilution Tracker
Shares outstanding grew 27918.7% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+27918.7%
Stock Issuance (TTM)
$7.4M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.16 | 0.20 | |
| Change vs Prior % | — | -11.8% | 14.2% | 47.3% | 70.4% | 40.2% | 367.4% | 1431.0% | 64.0% | 24.5% | |
| Stock Issuance | $127.2K | $160.1K | $0.00 | $449.4K | $5.4M | $790.7K | $11.1M | $3.1M | $415.0K | $7.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $112.3K | $0.00 | $0.00 | $619.9K | $1.6M | $508.1K | $1.4M | $805.8K | $1.6M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -13.2% | -108.7% | -102.5% | -61.4% | -94.4% | 661.4% | -875.4% | -121.5% | -323.4% | -87.3% | |
| ROA % | -6.5% | -105.3% | -76.9% | -59.8% | -87.8% | -885.1% | -144.6% | -52.0% | -63.4% | -44.3% | |
| ROIC % | -13.2% | -142.2% | -102.5% | -61.4% | -93.3% | 621.2% | -640.1% | -130.6% | -190.7% | -60.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -4633.5% | 52.0% | 11.1% | 3.3% | |
| Operating Income | 0.0% | -3869.9% | 59.8% | -121.0% | -1470.1% | -149.1% | 30.1% | 8.7% | 1.4% | |
| Net Income | 0.0% | -2934.1% | 47.4% | -121.0% | -1488.7% | -171.6% | 13.3% | 39.0% | 26.6% | |
| EPS (Diluted) | 0.0% | -3318.6% | 54.1% | -50.4% | -832.0% | -93.7% | 81.4% | 96.0% | 55.3% | |
| Operating Cash Flow | 0.0% | -782.1% | 40.5% | -314.8% | -946.4% | -143.4% | -24.7% | -7.3% | 30.0% | |
| Free Cash Flow | 0.0% | -555.1% | 69.3% | -271.6% | -990.5% | -125.4% | -24.5% | -7.3% | 30.0% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 594.9% | -65.3% | -10.4% | 49.1% | |
| SG&A Expense | 0.0% | 3869.9% | -59.8% | 121.0% | 1192.9% | 50.1% | 5.4% | -8.2% | -17.4% | |
| Total Assets | 0.0% | 86.9% | -28.0% | 184.0% | 981.8% | -73.1% | 430.7% | 69.6% | -39.8% | |
| Book Value / Share | 0.0% | 318.5% | -51.2% | 150.4% | 506.8% | -127.6% | 114.0% | -71.3% | -83.2% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 2304.5% | |
| Diluted Shares | 0.0% | -11.8% | 14.2% | 47.3% | 70.4% | 40.2% | 367.4% | 1431.0% | 64.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.09
10Y Low / Med / High75.36 / 1141.01 / 5648.42
EV/EBITDA0.90
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$8.03
Tangible Book / Share
$65.03
Net Current Assets / Share
$24.96
Graham Net-Net
$62.77
Cash / Share
$80.54
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -42436.20 | -1267.28 | -2760.65 | -1857.24 | -185.08 | -105.25 | -8.61 | -82.01 | -105.02 | -0.06 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 5648.42 | 1377.97 | 2824.62 | 1141.01 | 174.64 | -696.01 | 75.36 | 99.62 | 339.13 | 0.09 | |
| EV/EBITDA | -42693.06 | -1267.39 | -2756.22 | -1857.20 | -184.20 | -107.13 | -8.05 | -88.08 | -108.21 | 0.90 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-2.98
Distress
Piotroski F-Score
1
Weak